iiinova — where your digital self keeps evolving

Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). A trial investigated the addition of atezolizumab with SBRT. Find out more: spkl.io/633227p08M #ERSCongress @europeanrespsoc.bsky.social

Research in context panel for a paper published in The Lancet entitled "Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914):
a multicentre, open-label, superiority, phase 3, randomised controlled trial. Copyright: 2026 Elsevier Ltd. All rights reserved.

061

The Lancet @thelancet.com · 03/10/2026

Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation spkl.io/633277pLCt

Research in context panel. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

020

The Lancet @thelancet.com · 02/10/2026

Peripheral arterial disease (PAD) affects more than 300 million people worldwide—yet it remains under-recognised, underdiagnosed, and undertreated. A new Editorial discusses a Lancet Series aiming to address this major health burden: spkl.io/633207pL2I

Promotional card for The Lancet's October 3, 2026 Editorial. Image is of a Doppler ultrasound for ankle-brachial pressure index. Text reads 'Editorial: Peripheral arterial disease: counting what matters'.

093

The Lancet @thelancet.com · 02/10/2026

In our latest issue, a study evaluates whether wealth redistribution policies can mitigate the health impact of the current official development assistance (ODA) defunding crisis. Read the study & explore the full issue: spkl.io/633257p2T3

Cover of The Lancet's October 3, 2026 issue. Quote reads: We further project that, if current official development assistance defunding trends continue, more than 7.9 million additional deaths could occur in low-income and middle-income countries by 2030.

084

The Lancet @thelancet.com · 01/10/2026

Presented at #EASD2026—Mauritius is the first country to show a decreasing prevalence of diabetes and intermediate hyperglycaemia over time, using the objective, gold standard OGTT-based diagnostic criteria recommended by WHO. More in @thelancetendo.bsky.social: spkl.io/633217pvTl

Section of the first page of an article published in The Lancet Diabetes & Endocrinology entitled "Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study".

061

The Lancet @thelancet.com · 29/09/2026

New antibody treatment reduces number of new abnormal bone lesions by at least 90% in people with ultra-rare genetic disorder, fibrodysplasia ossificans progressiva (FOP), phase 3 study shows. Read now: spkl.io/633297T2st

Figure showing total number of new heterotopic bone lesions at week 56
Rate ratio versus placebo for the garetosmab 3 mg/kg group: 0·06 (95% CI
0·00–0·73); p=0·027. Rate ratio versus placebo for the garetosmab 10 mg/kg
group: 0·10 (0·01–0·76); p=0·026. *Rate is defined as the number of new
heterotopic bone lesions divided by the sample size. Copyright: 2026 Elsevier Ltd. All rights reserved.

0132

The Lancet @thelancet.com · 28/09/2026

Recent advances are redefining the understanding and management of hypoparathyroidism. In @thelancetendo.bsky.social, a Review summarises the scientific and medical findings presented at the Hypoparathyroidism 2025 Summit: spkl.io/633247puzI

Figure: CaSR structure and cell-specific signalling by multiple G-proteins pathway. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

063

The Lancet @thelancet.com · 27/09/2026

Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows. Find out more in The Lancet: spkl.io/633297TFyz #EANO2026 @eanoassociation.bsky.social

Kaplan–Meier estimates of disease-free survival by treatment group in the intention-to-treat population. Median follow-up was 64 months (IQR 50–75). HR=hazard ratio. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

095

The Lancet @thelancet.com · 26/09/2026

Our Clinical Resources hub is designed with clinicians in mind — clear, logical, and packed with the latest research. Discover how it can support your practice. spkl.io/633287rRiC

042

The Lancet @thelancet.com · 25/09/2026

On the cover, the new NUS–Lancet Pandemic Readiness through Institutions, Mobilising Communities, and Equity (PRIME) Commission. Read this & more in our latest issue: spkl.io/633207TtVr

Cover of The Lancet's September 26, 2026 issue. Quote reads: "PRIME offers a pathway to transform recurring vulnerabilities into a stronger and more resilient foundation for future health crises and to reshape pandemic readiness for the 21st century.

275

The Lancet @thelancet.com · 25/09/2026

Cancer genetic testing and precision oncology are advancing rapidly—but access is not. A new @thelancetoncol.bsky.social Commission sets out how health systems can scale these innovations equitably and sustainably: spkl.io/633287TYKi #WCC2026

Lancet infographic containing four scatter graphs showing precision oncology research is predominantly in countries with higher income, not higher cancer deaths. Under the graphs are a microscope, money bag, and graduation cap with arrows pointing up next to them. The three images represent 'more research infrastructure', 'more industry investment', and 'more academic capcity', respectively, as the reasons for the imbalance.

Lancet infographic containing an upside-down triangle graphic with four numbered sections. Next to the triangle is a table detailing a four-tier UHC framework for prioritising precision oncology interventions. The four tiers are Essential, Core expansion, Conditional, Evidence generation.

Lancet infographic representing the practical context-sensitive instrument for health systems planners and policy makers accompanying a four-tier UHC framework for prioritising precision oncology interventions. In one circle, there is a traffic light on green representing 'A system-readiness tool'. In a second circle is a person, light bulb, and cog system representing 'A workforce competency framework. In a third circle, there is a bar graph with an eye in a magnifying glass in front of it representing 'A monitoring and evaluation framework'.

0116

The Lancet @thelancet.com · 24/09/2026

Early-onset colorectal cancer (EO-CRC) is increasing globally. In The Lancet Regional Health - Eastern Mediterranean, authors assessed the burden, temporal trends, and future projections of EO-CRC across the WHO Eastern Mediterranean Region: spkl.io/633217TcwT

Map of the WHO Eastern Mediterranean Region showing EO-CRC burden in 2022. (A) Age-standardised incidence rates (ASIR per 100,000) of EO-CRC across countries. (B) Age-standardised mortality rates (ASMR per 100,000). Darker shades indicate higher rates. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY-NC-ND 4.0

076

The Lancet @thelancet.com · 23/09/2026

The current tests for endometrial cancer are invasive and often painful. In @lancetobgyn-wh.bsky.social, a study suggests that a simple non-invasive test could transform cancer screening for women with postmenopausal bleeding: spkl.io/633267TJai

Vaginal and urine samples showing endometrial cancer (true positive case; upper row) and no malignant cells (true negative case; lower row). Top row: SurePath (CytoRich Red, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) cytology slides (Papanicolaou stain): endometrial adenocarcinoma. Urine sample, × 600 magnification (left) and vaginal sample, × 600 magnification (right) from the study participant SMH0170 showing adenocarcinoma, clinical outcome grade 1 stage IB endometrioid adenocarcinoma, true positive. Bottom row: SurePath cytology slides (Papanicolaou stain): no malignant cells seen. Urine sample, × 400 magnification (left) and vaginal sample, × 600 magnification (right) from the study participant SMH0212 with no malignant cells seen, true negative. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

0128

The Lancet @thelancet.com · 22/09/2026

Peripheral arterial disease (PAD) affects more than 300 million people worldwide—yet it remains under-recognised, underdiagnosed, and undertreated. A new Series aims to address this major health burden: spkl.io/633217rwP1

Figure showing typical regions of vessel involvement in people with PAD and illustration of the life course of affected people from asymptomatic PAD through intermittent claudication to CLTI, with reported progression rates and major amputation risk as well as death rates at the symptomatic disease stage. CLTI=chronic limb-threatening ischaemia. PAD=peripheral arterial disease. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

0105

The Lancet @thelancet.com · 21/09/2026

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, find the EVOKE and EVOKE+ trials. Find out more ▶️ spkl.io/633297Tzif #WorldAlzheimersDay

Research in context panel for Lancet paper "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials". Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

055

The Lancet @thelancet.com · 21/09/2026

The field of Alzheimer’s disease has seen transformative advances that are beginning to reshape clinical practice. On #WorldAlzheimersDay, read a Seminar summarising the progress made and highlight the unmet needs and priorities for future research: spkl.io/633297Tz97

(A) MRI features of small vessel disease in an 86-year-old man with poorly controlled chronic hypertension. FLAIR shows severe periventricular white matter hyperintensities and lacunar strokes in basal ganglia (arrows). SWI shows multiple microbleeds in basal ganglia typical of hypertensive microangiopathy (arrows). (B) MRI features of cerebral amyloid angiopathy in a 71-year-old man with mild cognitive impairment and a positive [18F]-florbetaben amyloid PET. SWI revealed up to 12 microbleeds and three areas of focal cortical superficial siderosis (arrows), one in the right frontal lobe. FLAIR showed the typical multispot pattern of white matter hyperintensities in centri semiovale. T2 showed enlarged perivascular spaces in centri semiovale. FLAIR=fluid-attenuated inversion recovery. SWI=susceptibility weighted imaging.

093

The Lancet @thelancet.com · 20/09/2026

Blood test can identify signs of Alzheimer’s Disease decades before symptoms, suggests study in The Lancet. Find out more: spkl.io/633277ruqv #WorldAlzheimersDay

Research in context panel for the paper published in The Lancet entitled "Alzheimer’s disease neuropathology plasma biomarkers and cognition in midlife: a community-based cohort study". Copyright: 2026 Elsevier Ltd. All rights reserved.

0209

The Lancet @thelancet.com · 19/09/2026

ICYMI - A Series in @thelancetneuro.bsky.social explores how Alzheimer's disease clinical practice might evolve over the next 5–10 years, focusing on: ➡️ fluid biomarkers ➡️ neuroimaging ➡️ clinical pathways for cognitively unimpaired individuals Read now: spkl.io/633277rPsR #WorldAlzheimersMonth

Promotional card for The Lancet Neurology Series on Future Directions of Alzheimer's Disease and Related Disorders. Image on card: A gloved hand holds up a sample tube in front of a computer screen displaying brain scans. There is a rack of sample tubes in the foreground. Copyright: Tek Images/Science Photo Library.

042

The Lancet @thelancet.com · 18/09/2026

What if cancer prevention were as personalised as cancer treatment? The @gustaveroussy.fr–Lancet Lecture sets out the case for precision prevention & early detection—matching interventions to individual risk, while building the workforce & health systems needed to deliver them. spkl.io/633267rFOk

Quote from The Gustave Roussy-Lancet lecture on Precision prevention and early detection: framework for a new clinical cancer control pathway. Quote reads: "The defining challenge of the next decade of cancer control is not to build another test, but to build the discipline that uses them."

065

The Lancet @thelancet.com · 18/09/2026

Despite serious symptoms, asthma is often underdiagnosed and mismanaged, which—in the worst-case scenarios—can be fatal. A new Editorial explores the unmet needs of people living with severe asthma: spkl.io/633287rIyo

Promotional card for The Lancet September 19, 2026 Editorial. Image on card: Brown asthma inhaler and steroids. Text on card reads: "The unmet needs of people living with severe asthma".

041

The Lancet @thelancet.com · 18/09/2026

What makes a meta-analysis believable? In our latest issue, a new Viewpoint outlines how to identify meta-analyses that merit clinical confidence. Explore the full issue: spkl.io/633277rxvt

Cover of The Lancet September 19, 2026 issue. Quote reads: Meta-analyses are not definitive truths, but rather structured efforts to interpret incomplete, evolving, and sometimes inconsistent evidence.

0146

The Lancet @thelancet.com · 17/09/2026

ICYMI - A genetically modified pig kidney kept a man off dialysis for nine months before a successful human kidney transplant, according to a world-first report in The Lancet. Read now: spkl.io/633257r8p1

Figures showing (A) Total daily urine output (mL) during the first week after xenotransplantation. (B) Serum creatinine and eGFR throughout the xenograft period. Note that scales on y axes differ between plots. Vertical dashed lines indicate for-cause kidney biopsies—key histopathological findings are annotated: day 14, Banff IIA TCMR; day 176, MVI with endothelial injury; day 264, TMA with transplant glomerulopathy. (C) Serum sodium. (D) Serum potassium. All panels share a common x-axis representing days relative to xenotransplantation (day 0). eGFR=estimated glomerular filtration rate. MVI=microvascular inflammation. TCMR=T-cell-mediated rejection. TMA=thrombotic microangiopathy. Copyright: 2026 Elsevier Ltd. All rights are reserved.

02110

The Lancet @thelancet.com · 16/09/2026

⏰ Get writing—less than a month left to enter the 2025 Wakley Prize competition! Find out more about this year's theme: spkl.io/6332778MJb

Promotional card for The Lancet's Wakley Prize Essay Competition. Text on card reads: The Wakley Prize Essay Competition: A call for submissions. Background image is of Thomas Wakley, who founded The Lancet in 1823.

031

The Lancet @thelancet.com · 15/09/2026

What we eat and where we live have long been understood as determinants of health. But what we scroll, what algorithms feed us, and how platforms are designed are determinants of health too. Join us and @dthlab.bsky.social for the launch of a new Lancet Series ➡️ spkl.io/633247rMJu

Promotional image for the Lancet Series on the digital determinants of health, launching Monday 5 October at 13:00 BST.

0129

The Lancet @thelancet.com · 14/09/2026

A new study assessed the efficacy & safety of mitapivat in adults with transfusion-dependent thalassaemia. The study found that mitapivat significantly reduced the transfusion burden & was generally well tolerated, showing a favourable benefit–risk profile. Read: spkl.io/633207r84y

(A) TRR, defined as reduction of at least 50% in transfused red blood cell units with a reduction of at least two units of transfused red blood cells in any consecutive 12-week period until week 48 compared with baseline; patients withdrawn from the study before week 12 (day 85) were considered non-responders. (B) TRR2, defined as at least a 50% reduction in transfused red blood cell units in any consecutive 24-week period until week 48 compared with baseline; patients withdrawn from the study before week 24 (day 169) were considered non-responders. (C) TRR3, defined as at least a 33% reduction in transfused red blood cell units between week 13 and week 48 compared with baseline; patients withdrawn from the study before week 48 were considered non-responders. (D) TRR4, defined as at least a 50% reduction in transfused red blood cell units between week 13 and week 48 compared with baseline; patients withdrawn from the study before week 48 were considered non-responders.

031

The Lancet @thelancet.com · 13/09/2026

New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests. Find out more: spkl.io/633247RvuC

Research in context panel for a paper published in The Lancet entitled "Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study". Copyright: 2026 Elsevier Ltd. All rights reserved.

077

The Lancet @thelancet.com · 12/09/2026

Register to join Suzette Delaloge, Medical Oncologist and Researcher at Gustave Roussy, who will provide opening remarks and join a panel discussion at the inaugural Gustave Roussy–Lancet Lecture. 18 Sept | Paris + online Register: spkl.io/633287yTpp

Register to attend the Gustave Roussy-Lancet Lecture Series on Sept 18. Copyright: Gustave Roussy.

061

The Lancet @thelancet.com · 11/09/2026

New Editorial—Gene-editing therapies: delivering safely for patients spkl.io/633227Rs3G

Quote from The Lancet's September 12, 2026 Editorial. Quote reads: "The promise of therapeutic gene editing can only be realised with a renewed commitment to risk management, regulatory oversight, transparency, and a spirit of respectful cooperation between researchers, clinicians, and patients and their families."

051

The Lancet @thelancet.com · 11/09/2026

On the cover this week, authors of a new letter argue that global science can serve as a foundation for international cooperation, even when politics fails. Read this & more: spkl.io/633227RSlM

Cover of The Lancet's September 12, 2026 issue. Quote on cover: "Science cannot stop armies or resolve diplomatic failures. When formal political institutions weaken, science can preserve communication channels, common standards of evidence, and trust across borders."

1167

The Lancet @thelancet.com · 10/09/2026

In @thelancetneuro.bsky.social, a new Series explores how Alzheimer's disease clinical practice might evolve over the next 5–10 years, focusing on: ➡️ fluid biomarkers ➡️ neuroimaging ➡️ clinical pathways for cognitively unimpaired individuals Read now: spkl.io/633207R5si

085

The Lancet @thelancet.com · 09/09/2026

🆕 The Lancet Regional Health - Eastern Mediterranean has published its first piece of content online 📝 Farida Abougaziaa & Mohamed Salama discuss the overlooked mental health needs of older refugees in Egypt and the broader Eastern Mediterranean Region: spkl.io/633267RVvi

Quote from the first Comment published in The Lancet Regional Health - Eastern Mediterranean. Quote reads: "...strengthening the generation of age-disaggregated evidence and aging-sensitive intervention research may help inform more inclusive and contextually appropriate mental healthcare for refugees living in prolonged displacement."

031

The Lancet @thelancet.com · 09/09/2026

A genetically modified pig kidney kept a man off dialysis for nine months before a successful human kidney transplant, according to a world-first report in The Lancet. Read now: spkl.io/633247RJgK

0105

The Lancet @thelancet.com · 08/09/2026

In The Lancet Surgery & Anaesthesiology, Debra Leung and colleagues explore perioperative shared decision making through a global equity lens. Read now: tinyurl.com/myyb8h4y

070

The Lancet @thelancet.com · 08/09/2026

According to a new analysis published in @thelancetph.bsky.social, more than 2.7 billion people were exposed to second-hand smoke in 2023, contributing to nearly 1.7 million deaths. Explore the research: spkl.io/633247uhge #GBD @ihmeuw.bsky.social

Global and regional DALY rates attributable to second-hand smoke by cause, 2023: age-standardised rates for all ages (A) and age-specific rates for children aged 0–14 years (B). Bar heights represent cause-specific DALY rates attributable to second-hand smoke in the respective populations, globally and in each of the seven GBD super-regions. DALY=disability-adjusted life year. GBD=The Global Burden of Diseases, Injuries, and Risk Factors Study. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.

0113

The Lancet @thelancet.com · 07/09/2026

🫁 Lung cancer remains the leading cause of cancer-related death worldwide. A new Lancet–@lancetrespirmed.bsky.social Series, presented at #ERSCongress, evaluates the evolving therapeutic landscape across the major subtypes of lung cancer: spkl.io/633247uqza @europeanrespsoc.bsky.social

Promotional card for The Lancet-Lancet Respiratory Medicine Series on Therapeutics in Lung Cancer. The image on the card is a screen with a control panel. A simulated treatment device features fader slots. Icons above each slot indicate different lung cancer treatment approaches. Copyright: Lillian Li.

0103

The Lancet @thelancet.com · 07/09/2026

Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). A new trial investigated the addition of atezolizumab with SBRT. Find out more: spkl.io/633217uhKL #ERSCongress @europeanrespsoc.bsky.social

062

The Lancet @thelancet.com · 06/09/2026

How will the Meta settlement affect child health? Find out more in a new World Report: spkl.io/633277uWnL

Group of teenagers standing in a group while looking at their phones. Copyright: Thomas Barwick/Getty Images.

053

The Lancet @thelancet.com · 05/09/2026

Uptake of robotic-arm-assisted total knee replacement is increasing rapidly worldwide. Yet whether robotic systems improve outcomes is uncertain. A study investigated clinical efficacy & cost-effectiveness of Mako robotic-arm-assisted TKR versus conventional TKR: spkl.io/633237uWtL

Research in context panel for a paper published in The Lancet entitled "Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial".

172

The Lancet @thelancet.com · 04/09/2026

"...cardiovascular health should be central to maternal care." Our latest Editorial discusses cardiovascular health challenges during pregnancy and the need for better preventive care. Read now: spkl.io/633217umUh

Quote from The Lancet's September 5, 2026 Editorial. Quote reads: "New onset cardiovascular disease...complicates up to 15% of pregnancies and accounts for up to one-third of maternal deaths. A substantial proportion of this harm is potentially preventable..."

023

The Lancet @thelancet.com · 04/09/2026

Cardiovascular disease is one of the leading causes of maternal mortality & a major driver of morbidity. In our latest issue, a new Lancet Series examines the continuum of cardiovascular risk surrounding pregnancy. Read this & more: spkl.io/633267umrM

Cover of The Lancet's September 5, 2026 issue. Quote reads: "Cardiovascular disease is one of the leading causes of maternal mortality worldwide and a major contributor to long-term morbidity in women."

0112

The Lancet @thelancet.com · 01/09/2026

The Lancet Surgery & Anaesthesiology has published its first piece of content online 📝 Ntuli Kapologwe & colleagues highlight the importance of global surgery to global health and the need for synergy between the @who.int ECO Strategy & NSOAPS. Read now: tinyurl.com/3em6kser

053

The Lancet @thelancet.com · 31/08/2026

Pre-eclampsia continues to contribute substantially to perinatal morbidity & mortality, affecting up to 8% of pregnancies worldwide. A Seminar summarises current clinical & biomedical concepts related to pre-eclampsia, major advancements & remaining knowledge gaps: spkl.io/633207P5jq

Representation of the pathophysiology, mechanisms, and maternal presentation of pre-eclampsia. Copyright: 2026 Elsevier Ltd. All rights reserved.

065

The Lancet @thelancet.com · 30/08/2026

050

The Lancet @thelancet.com · 30/08/2026

Islatravir–lenacapavir has potential to be the first once-weekly complete oral single-tablet regimen for HIV-1 treatment, suggests ISLEND-2 trial in The Lancet. Explore the research: spkl.io/633227Pkrq

Research in context panel in a paper published in The Lancet entitled "Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial".

082

The Lancet @thelancet.com · 29/08/2026

More than 1 billion people are estimated to have a disability worldwide. To support a more inclusive research process & better evidence generation for people with disabilities, we updated our information for authors to include reporting on disability. Read more: spkl.io/633257OfbF

Quote from a Comment published in The Lancet. Quote reads: "...through collaboration with our authors, reviewers, readers, and research communities, we are committed to developing a more accessible and inclusive environment where everyone can contribute to and benefit from health research."

080

The Lancet @thelancet.com · 28/08/2026

Advances in biotechnology offer huge opportunities for early disease detection and therapy and vaccine development. At the same time, inadvertent or deliberate misuse carries catastrophic health risks. How do we balance the two? Find out more: spkl.io/633237P5fH

Promotional card for The Lancet's Aug 29, 2026 Editorial. Image: a Centers for Disease Control and Prevention (CDC) scientist prepares an experiment inside of a class II biological safety cabinet (BSC). Text: Editorial: Biosecurity in a rapidly changing world.

061

The Lancet @thelancet.com · 28/08/2026

The lessons from past Ebola outbreaks are well known. The challenge is putting them into practice. A new Comment calls for communities and civil society to have greater agency in shaping outbreak responses—not simply receiving them. Read this & more: spkl.io/633217P5X3

Cover of The Lancet's August 29, 2026 issue. Quote reads: "The most important lesson from Ebola is not simply that communities matter; it is that sustainable outbreak control depends on citizens and civil society being recognised as legitimate partners in the production of health security."

0122

The Lancet @thelancet.com · 27/08/2026

“My doctor told me to lose weight.” In a new essay, Lauren Hartman examines the unintended consequences that weight-focused conversations can have for young people—and calls for a more nuanced approach to health beyond weight and BMI. Read now: spkl.io/633277PBlL

Quote from a Perspective piece published in The Lancet. Quote reads: "Together, we can shape the experiences for children and future generations, so that they associate the doctor's office with a place of respect, healing, and safety."

062

The Lancet @thelancet.com · 26/08/2026

🚨 There is still time to register for @eclinicalmed.bsky.social's webinar "Transforming the Landscape of #GynaecologicalCancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies". Register now: spkl.io/633237OAT3 Read the Series: spkl.io/633247OATO

Promotional card for the webinar "Transforming the Landscape of Gynaecological Cancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies".

062

The Lancet @thelancet.com · 26/08/2026

Register this week to save on fees and join world-renowned speakers to explore critical topics in #diabetes research, prevention, and care. 👉 Book your place by Sep 4, 2026 to save on fees: spkl.io/633217MvTV

The Lancet Summit: shaping the future of diabetes prevention. Image credit: Ixefra / Getty Images

031